Kristie L. Kahl is vice president of content at MJH Life Sciences, overseeing CURE®, CancerNetwork®, the journal ONCOLOGY, Targeted Oncology, and Urology Times®. She has been with the company since November 2017.
She is a graduate of Rider University, where she acquired a Bachelors of Art in journalism, as well as a graduate of Temple University, where she received her Masters of Science in Sports Management.
Follow Kristie on Twitter at @KristieLKahl, or email her at kkahl@mjhlifesciences.com.
EFS Improvement Observed With Neoadjuvant and Adjuvant Nivolumab in Resectable NSCLC
October 21st 2023Neoadjuvant nivolumab combination followed by surgery and adjuvant nivolumab show an improvement in event-free survival for patients with previously untreated resectable stage II to IIIB non-small cell lung cancer.
Pembrolizumab/Chemo Improves EFS Vs Chemo in High-Risk TNBC
October 20th 2023Event-free survival benefits with pembrolizumab plus chemotherapy in the phase 3 KEYNOTE-522 trial appear to be consistent in triple-negative breast cancer across subgroups based on nodal status, tumor size, and PD-L1 status.
Tumor Treating Fields Plus SOC May Benefit OS in Metastatic NSCLC
June 7th 2023The results of the phase 3 LUNAR trial evaluating tumor treating fields plus standard-of-care therapies among patients with metastatic non–small cell lung cancer are “encouraging,” according to an expert from Winship Cancer Institute of Emory University.
Ongoing Trials Aim to Determine Best Regimen for Transplant-Ineligible Patients With Myeloma
March 1st 2023Luciano J. Costa, MD, PhD, discussed additional studies evaluating various treatment regimens for transplant-ineligible patients with newly diagnosed multiple myeloma, aiming to determine the best standard in this population.
GRIFFIN Trial Supports Use of Dara-VRd in Transplant-Eligble Patients With Myeloma
February 28th 2023Luciano J. Costa, MD, PhD, discussed the results from the phase 2 GRIFFIN study, designed to evaluate the combination of daratumumab, bortezomib, lenalidomide, and dexamethasone in transplant-eligible patients with multiple myeloma.
MAIA trial Supports Use of D-Rd in Transplant-Ineligible Patients With Myeloma
February 27th 2023Luciano J. Costa, MD, PhD discussed updating findings from the phase 3 MAIA trial of the triplet combination of daratumumab, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma.